TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Scilex Holding Company ( (SCLX) ).
Scilex Holding Company announced the completion of its two-tranche equity financing in Datavault AI Inc., with the second tranche closing on November 25, 2025, following stockholder approval. The investment, valued at approximately $583.3 million, was made in Bitcoin, and both companies plan to enhance collaboration in Real World Asset tokenization, potentially impacting their market positioning and growth in 2026 and beyond.
The most recent analyst rating on (SCLX) stock is a Buy with a $770.00 price target. To see the full list of analyst forecasts on Scilex Holding Company stock, see the SCLX Stock Forecast page.
More about Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases. The company targets indications with high unmet needs and large market opportunities, offering products such as ZTlido, ELYXYB, and Gloperba, and developing candidates like SP-102, SP-103, and SP-104.
Average Trading Volume: 213,966
Technical Sentiment Signal: Sell
Current Market Cap: $154.4M
See more data about SCLX stock on TipRanks’ Stock Analysis page.